Rapamycin was isolated in the 1970s from a bacterium found in the soil of Easter Island (Rapa Nui), and has been used for decades to suppress the immune system in organ-transplant patients. The interest comes from its effect on mTOR, the pathway that governs how cells sense growth and nutrients — the same cellular "self-cleaning" mechanism we cover in our autophagy article. mTOR is also suppressed by caloric restriction and fasting, which is why some researchers describe rapamycin as "a pill that mimics caloric restriction."
The animal evidence is stronger than for almost any other longevity compound or supplement. The human side is far newer and far more modest. We treat the two separately below.
A 2025 meta-analysis in Aging Cell compared the lifespan effects of rapamycin and metformin against caloric restriction. Ivimey-Cook and colleagues pooled 911 effect sizes from 167 papers, spanning 8 vertebrate species from fish to primates. The result is clear-cut: caloric restriction robustly and consistently extends lifespan; rapamycin extends lifespan with almost the same consistency across species. Metformin, by contrast, showed no clear benefit.
That puts rapamycin in a different tier among longevity drugs — metformin, often mentioned in the same breath, didn't come close in this analysis. But the authors add their own caveat: high heterogeneity between studies and publication bias (positive results being more likely to get published) both shape the result. The true effect size may be somewhat smaller than reported.
The largest, longest crowd-funded trial testing rapamycin in healthy people, PEARL, was published in Aging in April 2025 (Moel et al.). This 48-week decentralized, double-blind, placebo-controlled trial split healthy adults aged 50-85 into three arms: placebo, 5 mg of compounded rapamycin weekly, or 10 mg weekly.
Two things are worth flagging here. First, the trial's actual target — visceral fat — didn't move, so "rapamycin burns fat" isn't a claim this data supports. Second, the positive findings showed up only in women and only on secondary measures; why the effect split by sex isn't clear, and generalizing from one trial is risky.
In August 2025, a systematic review by Jacob Hands of George Washington University, published in Aging, asked exactly this question in its title: "What is the clinical evidence to support off-label rapamycin therapy in healthy adults?" The answer is blunt: there is no clear clinical evidence that the strong results seen in animals carry over to healthy humans in the same way. The review notes that some trials with different mTOR inhibitors found stronger immune responses and fewer respiratory infections in older adults, and other trials reported improvements in subjective well-being and physical performance measures such as walking speed and strength — but the author closes with a call for "larger, better-designed human trials," not a recommendation.
The honest answer, based on what we have: not yet, and certainly not as a self-directed decision aimed at slowing aging. The animal evidence is genuinely strong, which is exactly why rapamycin is the most closely watched compound in longevity research. But the best human data we have, PEARL, found no effect at all on its primary target; the positive effects it did find were secondary, limited to women, and come from a single trial.
Safety also splits into two different pictures. Low-dose, weekly (intermittent) use, over a 48-week window, in a selected and relatively healthy group, didn't raise serious adverse events. But years of high-dose rapamycin use in transplant patients is tied to immunosuppression, raised cholesterol and raised blood sugar — established, serious risks. The long-term (multi-year) safety of low-dose longevity use hasn't been tested yet.
Rapamycin is a prescription drug in Turkey and most countries; use for longevity is not an approved indication. Off-label prescribing through some clinics is becoming more common, but it requires medical supervision and regular bloodwork (lipid panel, blood sugar, immune markers) — sourcing and using it on your own, outside medical oversight, is not advisable.
No human study shows this. A large 2025 meta-analysis found that rapamycin extended lifespan in 8 vertebrate species almost as much as caloric restriction, but that data comes from mice, fish and other animals. In the largest human safety trial, PEARL, the primary outcome (visceral fat) did not change at all — and that trial wasn't designed to measure lifespan in the first place.
In this 48-week randomized controlled trial in healthy adults aged 50-85, visceral fat did not change at any dose. But women on the 10 mg weekly dose saw an increase in lean tissue mass and less pain, and women on 5 mg saw improvements in subjective well-being and general health. Men showed no significant change at either dose.
The PEARL trial reported that low-dose, intermittent (weekly) use over 48 weeks did not raise the rate of serious adverse events compared to placebo. But that's a short window in a selected, relatively healthy group. Rapamycin used long-term at high doses, as in organ transplant patients, carries known risks: immunosuppression, raised cholesterol and raised blood sugar. Using it without a prescription or medical supervision is not advisable.
The PEARL trial used 5 mg or 10 mg per week. That's a research protocol, not a personal dosing recommendation. Rapamycin is a prescription drug in Turkey and most countries; longevity use is not an approved indication and can only be considered under a doctor's supervision.
"In animals, rapamycin is the closest rival to caloric restriction. In humans, the best trial we have didn't give us the result we hoped for — just more modest, sex-specific clues."
— Vivelong Longevity Science Team